Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
Background. Accumulating evidence suggests that patients with type 2 diabetes mellitus and hyperinsulinemia are at an increased risk of developing malignancies. It remains to be fully elucidated whether the use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affects...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2019/7676909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160207659794432 |
|---|---|
| author | Abraham Nigussie Mekuria Yohanes Ayele Assefa Tola Kirubel Minsamo Mishore |
| author_facet | Abraham Nigussie Mekuria Yohanes Ayele Assefa Tola Kirubel Minsamo Mishore |
| author_sort | Abraham Nigussie Mekuria |
| collection | DOAJ |
| description | Background. Accumulating evidence suggests that patients with type 2 diabetes mellitus and hyperinsulinemia are at an increased risk of developing malignancies. It remains to be fully elucidated whether the use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affects cancer incidence in subjects with type 2 diabetes mellitus. Objective. A systematic review and meta-analysis was performed to compare the risk of cancer incidence associated with monotherapy with metformin compared with monotherapy with sulfonylureas in type 2 diabetes mellitus patients. Methods. Search was performed throughout MEDLINE/PubMed, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov up until December 2018. In this meta-analysis, each raw data (unadjusted) and study-specific (adjusted) relative risks (RRs) was combined and the pooled unadjusted and adjusted RRs with the 95% CI were calculated using the random-effects model with inverse-variance weighting. Heterogeneity among the studies was evaluated using I2 statistics. Publication bias was evaluated using the funnel plot asymmetry test. The Newcastle-Ottawa scale (NOS) was used to assess the study quality. Results. A total of 8 cohort studies were included in the meta-analysis. Obvious heterogeneity was noted, and monotherapy with metformin was associated with a lower risk of cancer incidence (unadjusted RR=0.74, 95% CI: 0.55-0.99, I2=97.89%, p<0.00001; adjusted RR=0.76, 95% CI: 0.54–1.07, I2=98.12%, p<0.00001) compared with monotherapy with sulfonylurea, using the random-effects model with inverse-variance weighting. Conclusions. According to this review, the monotherapy with metformin appears to be associated with a lower risk of cancer incidence than monotherapy with sulfonylurea in patients with type 2 diabetes. This analysis is mainly based on cohort studies, and our findings underscore the need for large-scale randomized controlled trials to establish the effect of metformin monotherapy, relative to sulfonylureas monotherapy on cancer. |
| format | Article |
| id | doaj-art-b274e2c5f5c642e5b12d01f3fe6546bf |
| institution | OA Journals |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-b274e2c5f5c642e5b12d01f3fe6546bf2025-08-20T02:23:12ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/76769097676909Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-AnalysisAbraham Nigussie Mekuria0Yohanes Ayele1Assefa Tola2Kirubel Minsamo Mishore3Department of Pharmacology, College of Health and Medical Sciences, Haramaya University, Harar, EthiopiaDepartment of Clinical Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, EthiopiaDepartment of Epidemiology and Biostatistics, College of Health and Medical Sciences, Haramaya University, Harar, EthiopiaDepartment of Clinical Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, EthiopiaBackground. Accumulating evidence suggests that patients with type 2 diabetes mellitus and hyperinsulinemia are at an increased risk of developing malignancies. It remains to be fully elucidated whether the use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affects cancer incidence in subjects with type 2 diabetes mellitus. Objective. A systematic review and meta-analysis was performed to compare the risk of cancer incidence associated with monotherapy with metformin compared with monotherapy with sulfonylureas in type 2 diabetes mellitus patients. Methods. Search was performed throughout MEDLINE/PubMed, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov up until December 2018. In this meta-analysis, each raw data (unadjusted) and study-specific (adjusted) relative risks (RRs) was combined and the pooled unadjusted and adjusted RRs with the 95% CI were calculated using the random-effects model with inverse-variance weighting. Heterogeneity among the studies was evaluated using I2 statistics. Publication bias was evaluated using the funnel plot asymmetry test. The Newcastle-Ottawa scale (NOS) was used to assess the study quality. Results. A total of 8 cohort studies were included in the meta-analysis. Obvious heterogeneity was noted, and monotherapy with metformin was associated with a lower risk of cancer incidence (unadjusted RR=0.74, 95% CI: 0.55-0.99, I2=97.89%, p<0.00001; adjusted RR=0.76, 95% CI: 0.54–1.07, I2=98.12%, p<0.00001) compared with monotherapy with sulfonylurea, using the random-effects model with inverse-variance weighting. Conclusions. According to this review, the monotherapy with metformin appears to be associated with a lower risk of cancer incidence than monotherapy with sulfonylurea in patients with type 2 diabetes. This analysis is mainly based on cohort studies, and our findings underscore the need for large-scale randomized controlled trials to establish the effect of metformin monotherapy, relative to sulfonylureas monotherapy on cancer.http://dx.doi.org/10.1155/2019/7676909 |
| spellingShingle | Abraham Nigussie Mekuria Yohanes Ayele Assefa Tola Kirubel Minsamo Mishore Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis Journal of Diabetes Research |
| title | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| title_full | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| title_fullStr | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| title_short | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| title_sort | monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2019/7676909 |
| work_keys_str_mv | AT abrahamnigussiemekuria monotherapywithmetforminversussulfonylureasandriskofcancerintype2diabeticpatientsasystematicreviewandmetaanalysis AT yohanesayele monotherapywithmetforminversussulfonylureasandriskofcancerintype2diabeticpatientsasystematicreviewandmetaanalysis AT assefatola monotherapywithmetforminversussulfonylureasandriskofcancerintype2diabeticpatientsasystematicreviewandmetaanalysis AT kirubelminsamomishore monotherapywithmetforminversussulfonylureasandriskofcancerintype2diabeticpatientsasystematicreviewandmetaanalysis |